Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

BACKGROUND: Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK(+) non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-ge...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Christopoulos, Petros, Bozorgmehr, Farastuk, Brückner, Lena, Chung, Inn, Krisam, Johannes, Schneider, Marc A., Stenzinger, Albrecht, Eickhoff, Regina, Mueller, Daniel W., Thomas, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8240323/
https://ncbi.nlm.nih.gov/pubmed/34182952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08460-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados